National Health Investors Inc. (NYSE:NHI) recently announced its normalized Funds From Operations (“FFO”) and net income for the three and six months ended June 30, 2010. Normalized FFO improved 22.8% to $0.70 per basic and diluted common share compared with $0.57 in the same period of 2009. The Company announced it will pay a third quarter dividend of $0.605 per common share to shareholders of record on September 30, 2010 and payable on November 10, 2010. This dividend represents an increase of 5.2% from the second quarter dividend which would represent an annualized dividend of $2.42 per share.

National Health Investors, Inc. is a healthcare real estate investment trust that specializes in the financing of healthcare real estate by purchase and leaseback transactions and by mortgage loans.

Proteonomix, Inc. (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.

PROT recently announced further developments with its Joint Venture Company, XGEN Medical LLC (”XGen”) towards implementing operations in the United Arab Emirates.

Proteonomix is the majority shareholder in XGen with the balance held by an anonymous investor group. Proteonomix personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase.

This wholly owned subsidiary will be the vehicle to conduct business in the GCC countries. XGen has filed the corporate papers and has established banking relations with a local bank both for receipt of the initial investment of $5 million and towards further financing expanded services in the region.

It was further announced that XGen has expanded its talks within the region beyond a license for manufacture of and treatment with Proteonomix cellular material. Discussions are now further encompassing both the construction of XGen's own manufacturing and treatment facility within the U.A.E. and on funding phased trials for one or more of Proteonomix's proprietary cellular materials for treatment of disease.

In addition, Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products.

Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

For more information about this company please visit http://www.proteonomix.com

The New York Times Company (NYSE:NYT) is celebrating the 40th anniversary of the Op-Ed page with a look back at some of the most acclaimed and debated Op-Ed contributors throughout the years, including past presidents and foreign leaders, Nobel Laureates and Pulitzer Prize winners. The Times on Sunday, Sept. 26 will offer a special standalone print section with a selection of notable Op-Ed voices and topics.

The New York Times Company is a leading media company with 2009 revenues of $2.4 billion.

Newcastle Investment Corp. (NYSE:NCT) recently reported that for the quarter ended June 30, 2010, income applicable to common stockholders (“GAAP income”) was $118 million, or $1.90 per diluted share, compared to a loss applicable to common stockholders of $47 million, or $0.90 per diluted share, for the quarter ended June 30, 2009.

Newcastle Investment Corp. owns and manages a portfolio of diversified, credit sensitive real estate debt that is primarily financed with match funded debt.

CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.

Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup

PLEASE BE SURE TO VISIT CRWESELECT.NING.COM

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

PROTcrweselect0925